The macrolides

Expert Opinion on Investigational Drugs

Volumn 11, Issue 2, 2002, Pages 189-215

  Blondeau, Joseph M ^a   DeCarolis, Emidio ^a   Merzler, Kelli L ^a   Hansen, Glen T ^a  

^a ROYAL UNIVERSITY HOSPITAL   (Canada)

Author keywords

Azithromycin; Clarithromycin; Macrolides

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; ASTEMIZOLE; AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; CARBAMAZEPINE; CEFACLOR; CEFIXIME; CEFUROXIME; CEFUROXIME AXETIL; CLARITHROMYCIN; CLINDAMYCIN; CYCLOSPORIN; DIGOXIN; DISOPYRAMIDE; DOXYCYCLINE; ERGOTAMINE; ERYTHROMYCIN; GREPAFLOXACIN; LEVOFLOXACIN; MACROLIDE; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFABUTIN; ROXITHROMYCIN; SPARFLOXACIN; TERFENADINE; THEOPHYLLINE; UNINDEXED DRUG; VALPROIC ACID; WARFARIN; ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG ELIMINATION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG SENSITIVITY; DRUG STABILITY; DRUG STRUCTURE; DRUG TISSUE LEVEL; DRUG TOLERABILITY; DRUG TRANSFORMATION; DRUG UPTAKE; DRUG URINE LEVEL; GASTROINTESTINAL SYMPTOM; GENITAL TRACT INFECTION; GRAM NEGATIVE BACTERIUM; HUMAN; LYME DISEASE; MYCOBACTERIOSIS; RESPIRATORY TRACT INFECTION; REVIEW; SKIN INFECTION; SOFT TISSUE INFECTION; BACTERIAL INFECTION; COMPARATIVE STUDY; CORONARY ARTERY ATHEROSCLEROSIS; DRUG INTERACTION; STRUCTURE ACTIVITY RELATION;

ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; CLINICAL TRIALS; CORONARY ARTERIOSCLEROSIS; DRUG INTERACTIONS; DRUG RESISTANCE, BACTERIAL; HUMANS; MACROLIDES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0036166365     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.11.2.189     Document Type: Review

References (222)

1. Azithromycin and clarithromycin: Overview and comparison with erythromycin
2. The newer macrolides - Azithromycin and clarithromycin
3. Erythromycin, clarithromycin and azithromycin: Are the differences real?
4. Macrolides: A Canadian Infectious Disease Society position paper
5. A critical review of the changing etiology of community-acquired pneumonia and the clinical impact of antimicrobial resistance
6. New directions for macrolide antibiotics: Structure modifications and in vitro activity
7. Azithromycin - Spectrum of activity, pharmacokinetics and clinical applications
8. Comparison of the acid stability of azithromycin and erythromycin A
9. Clinical pharmacokinetic properties of the macrolide antibiotics. Effects of age and various pathophysiological states
10. Relationship of high tissue concentrations of azithromycin to bactericidal activity and efficacy in vivo
11. Clarithromycin and azithromycin: New macrolide antibiotics
12. Mechanism of action of spiramycin and other macrolides
13. Inducible resistance to macrolides, lincosamides, and streptogramin type B antibiotics: The resistance phenotype, its biological diversity and structural elements that regulate expression - A review
14. Functional consequences of binding macrolides to ribosomes
15. Spectrum and mode of action of azithromycin (CP-62,993), a new 15-membered-ring macrolide with improved potency against gram-negative organisms
16. Comparative in vitro potencies of nine new macrolides
17. Azithromycin and clarithromycin
18. Multiple mechanisms of erythromycin resistance
19. Pneumococcal macrolide resistance - Myth or reality?
20. Plasmid-determined resistance to antimicrobial drugs and toxic metal ions in bacteria
21. New macrolides active against Streptococcus pyogenes with inducible or constitutive type of macrolide-lincosamide-streptogramin B resistance
22. The Canadian Antimicrobial Study Group: Susceptibility of Canadian isolates of Haemophilus influenzae, Moraxella catarrhalis and Streptococcus pneumoniae to oral antimicrobial agents
23. Macrolide-resistant Streptococcus pneumoniae in Canada during 1998-1999: Prevalence of mef(A) and erm(B) and susceptibilities to ketolides
24. The role of newer macrolides in the treatment of community-acquired respiratory tract infection. A review of experimental and clinical data
25. Antimicrobial susceptibility patterns of respiratory pathogens - A global perspective
26. Resistance surveillance of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis isolated in Asia and Europe, 1997-1998
27. Surveillance of antmicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis in the United States in 1996-1997 respiratory season
28. A 1994-94 survey of Haemophilus influenzae susceptibility to ten orally administered agents: A 187 clinical laboratory center sample in the United States
29. Antimicrobial susceptibility of community-acquired lower respiratory tract bacterial pathogens isolated in the UK during the 1995-1996 cold season
30. Trends in the antimicrobial susceptibility of bacterial respiratory tract pathogens - Findings of the Alexander Project 1992-1996
31. The Sentry Participants Group (North America): Antibacterial activity of 41 antimicrobials tested against over 2773 bacterial isolates from hospitalized patients with pneumonia - I-results from the SENTRY Program (North America, 1998)
32. Comparative in vitro activity of 16 antimicrobials against 5442 community-acquired, lower respiratory tract pathogens: The Alexander Project, 1997
33. Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in the United States during 1999-2000, including a comparison of resistance rates since 1994-1995
34. Prevalence of ermAm and mefE in penicillin resistant Streptococcus pneumoniae
35. Comparative activities of amoxycillin and 10 other oral drugs against penicillin-susceptible and resistant S. pneumoniae strains recently isolated in Italy
36. Prevalence and characterization of the mechanisms of macrolide resistance in 830 penicillin-susceptible S. pneumoniae isolated in Italy during 1993-1997
37. The pharmacokinetics of azithromycin in human serum and tissues
38. The development of macrolides: Clarithromycin in perspective
39. Clinical toleration and safety of azithromycin
40. Intracellular accumulation of azithromycin by cultured human fibroblasts
41. Stimulation with cytokines enhances penetration of azithromycin into human macrophages
42. In vitro and in vivo uptake of azithromycin (CP-62,993) by phagocytic cells: Possible mechanism of delivery and release at sites of infection
43. The new macrolides: Azithromycin and clarithromycin
44. Azithromycin clinical pharmacokinetics
45. Azithromycin: A review of its pharmacological properties and use as 3-day therapy in respiratory tract infections
46. The pharmacokinetics and inflammatory fluid penetration of orally administered azithromycin
47. Multiple dose pharmacokinetics of azithromycin following 1 hour intravenous infusions in hospitalized patients with community-acquired pneumonia
48. Clinical pharmacokinetics of clarithromycin
49. Drug-food interaction potential of clarithromycin, a new macrolide antimicrobial
50. Absolute bioavailabity of clarithromycin after oral administration in humans
51. Clarithromycin, a unique macrolide: A pharmacokinetic, microbiological and clinical overview
52. Metabolism and disposition of clarithromycin in man
53. Effect of moderate or severe hepatic impairment on clarithromycin pharmacokinetics
54. Pharmacokinetics of new macrolides
55. Clinical toleration and safety of azithromycin in adults and children
56. The macrolides: Erythromycin, clarithromycin and azithromycin
57. Overview of the tolerability profile of clarithromycin in preclinical and clinical trials
58. A comparative safety and efficacy study of clarithromycin and erythromycin stearate in community-acquired pneumonia
59. Drug intolerance to high-dose clarithromycin among elderly patients
60. Cholestatic hepatitis in a patient who received clarithromycin therapy for a Mycobacterium chelonae lung infection
61. Fulminant hepatic failure associated with clarithromycin
62. Pancreatitis induced by clarithromycin
63. A clarithromycin-induced myasthenic syndrome
64. Pharmacokinetic drug interactions of macrolides
65. Drug interactions of macrolides: Emphasis on dirithromycin
66. Pharmacokinetic interactions of the macrolide antibiotics
67. Digoxin toxicity secondary to clarithromycin therapy
68. The mechanism of cyclosporine toxicity induced by clarithromycin
69. Clarithromycin-associated digoxin toxicity in the elderly
70. Life-threatening interaction between clarithromycin and disopyramide
71. Interaction between clarithromycin and oral anticoagulants
72. Effect of combination therapy with ciprofloxacin and clarithromycin on theophylline pharmacokinetics in healthy volunteers
73. Cisapride: Drug interactions of clinical significance
74. Interaction between midazolam and clarithromycin: Comparison with azithromycin
75. Possible role of intestinal P-450 enzyme system in a cyclosporine-clarithromycin interaction
76. Pharmacokinetics of clarithromycin and zidovudine in patients with AIDS
77. Drug interaction between clarithromycin and oral zidovudine in HIV-1 infected patients
78. Clarithromycin and zidovudine pharmacokinetic study
79. Clarithromycin lowers plasma zidovudine levels in persons with human immunodeficiency virus infection
80. Effect of clarithromycin on the pharmacokinetics of 2′,3′-dideoxyinosine in patients who are seropositive for human immunodeficiency virus
81. Incidence of antibiotic resistant Streptococcus pneumoniae and beta-lactamase-positive Haemophilus influenzae in clinical isolates from patients with otitis media
82. Guidelines for the initial management of adults with community-acquired pneumonia: Diagnosis, assessment of severity and initial antimicrobial therapy
83. New and emerging etiologies for community-acquired pneumonia with implications for therapy: A prospective multicenter study of 359 cases
84. Empirical therapy of community-acquired pneumonia: Macrolides are not ideal choices
85. Macrolides are ideal for empiric therapy of community-acquired pneumonia in the immunocompetent host
86. Multicenter evaluation of azithromycin and cefaclor in acute lower respiratory tract infections
87. Effect of macrolides as part of initial empiric therapy on length of stay in patients hospitalized with community-acquired pneumonia
88. Associations between initial antimicrobial therapy and medical outcomes for hospitalized elderly patients with pneumonia
89. Analysis under Cox's failure time model using weighted least squares
90. Hazard rate models with covariates
91. Incidence of community-acquired pneumonia requiring hospitalization: Results of a population-based active surveillance study in Ohio
92. Studies suggest a darker side of "benign" microbes
93. Infections due to species of Mycoplasma and Ureaplasma: An update
94. Antimicrobial susceptibility and therapy of infections caused by Chlamydia pneumoniae
95. Chlamydia pneumoniae as a new source of infectious outbreaks in nursing homes
96. Community-acquired pneumonia in adults: Guidelines for management
97. Practice guidelines for the management of community-acquired pneumonia in adults
98. Canadian guidelines for the initial management of community-acquired pneumonia: An evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society
99. Etiology, susceptibility and treatment of acute bacterial exacerbations of complicated chronic bronchitis in the primary care setting: Ciprofloxacin 750 mg bid versus clarithromycin 500 mg bid
100. Efficacy of oral ciprofloxacin vs clarithromycin for treatment of acute bacterial exacerbations of chronic bronchitis
101. A comparison of azithromycin and penicillin V for the treatment of streptococcal pharyngitis
102. Clarithromycin versus penicillin in the treatment of streptococcal pharyngitis
103. A comparative study of clarithromycin and penicillin VK in the treatment of outpatients with streptococcal pharyngitis
104. 1997 USPHS/IDSA Guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus
105. A comparative study of clarithromycin and amoxicillin suspensions in the treatment of pediatric patients with acute otitis media
106. Azithromycin compared with cephalexin in the treatment of skin and skin structure infections
107. Clarithromycin in the treatment of skin and skin structure infections: Two multicenter clinical studies
108. A controlled trial of a single dose of azithromycin for the treatment of Chlamydial urethritis and cervicitis
109. Clarithromycin as monotherapy for eradication of Helicobacter pylori: A randomized double-blind trial
110. Susceptibility of clinical isolates of Campylobacter pylori to twenty-one antimicrobial agents
111. In vitro activity of azithromycin against intracellular Helicobacter pylori
112. Azithromycin levels in plasma and gastric tissue, juice and mucus
113. Triple therapy with azithromycin, omeprazole and amoxicillin is highly effective in the eradication of Helicobacter pylori: A controlled trial versus omeprazole plus amoxicillin
114. Azithromycin triple therapy for Helicobacter pylori infection: Azithromycin, tetracycline and bismuth
115. The use of azithromycin in short-term low-dose triple therapies for Helicobacter pylori infection
116. Cure of Helicobacter pylori infection in the elderly: Effects of eradication on gastritis and serological markers
117. A comparative trial of short term therapy with omeprazole plus either amoxycillin or azithromycin for Helicobacter pylori eradication
118. Short-term low-dose triple therapy with azithromycin, metronidazole and lansoprazole appears highly effective for the eradication of Helicobacter pylori
119. Initial clarithromycin monotherapy for Mycobacterium-avium-intracellulare complex lung disease
120. Clarithromycin and other antimicrobial agents in the treatment of disseminated Mycobacterium avium infections in patients with acquired immunodeficiency syndrome
121. Orally administered clarithromycin for the treatment of systemic Mycobacterium avium complex infection in children with acquired immunodeficiency syndrome
122. In vitro activities of several new macrolide antibiotics against Mycobacterium avium complex
123. Azithromycin, rifabutin and rifapentine for treatment of prophylaxis of Mycobacterium avium complex in rats treated with cyclosporine
124. Azithromycin therapy for disseminated Mycobacterium avium intracellular in AIDS patients
125. A randomized trial of clarithromycin as prophylaxis against disseminated Mycobacterium avium complex infection in patients wth advanced acquired immunodeficiency syndrome
126. Comparative in vitro activities of clarithromycin, azithromycin and erythromycin against Borrelia burgdorferi
127. Comparative antimicrobial activity of the new macrolides against Borrelia burgdorferi
128. In vitro and in vivo susceptibility of Borrelia burgdorferi to azithromycin
129. Treatment of early Lyme disease
130. Erythema migrans: Comparison of treatment with azithromycin, doxycycline and phenoxymethyl-penicillin
131. Azithromycin versus penicillin V for the treatment of early Lyme borreliosis
132. Azithromycin compared with amoxicillin in the treatment of erythema migrans: A double-blind, randomized, controlled trial
133. Azithromycin and doxycycline for treatment of Borrelia culture-positive erythema migrans
134. In vitro evaluation of the activities of azithromycin alone and combined with pyrimethamine against Toxoplasma gondii
135. Results from recent therapeutic trials for opportunistic infections from the United States
136. Rapid response of AIDS-related bacillary angiomatosis to azithromycin
137. Azithromycin for the treatment of cat-scratch disease
138. Rhodococcus equi in CAPD-associated peritonitis treated with azithromycin
139. Infections due to Rhodococcus equi in three HIV-infected patients: Microbiological findings and antibiotic susceptibility
140. Azithromycin therapy for Cryptosporidium parvum infection in four children infected with human immunodeficiency virus
141. Pilot studies of azithromycin, letrazuril and paromomycin in the treatment of cryptosporidiosis
142. Clarithromycin and azithromycin
143. Clarithromycin-minocycline combination as salvage therapy for toxoplasmosis in patients infected with human immunodeficiency virus
144. Pyrimethamine-clarithromycin combination for therapy of acute Toxoplasma encephalitis in patients with AIDS
145. Breakthrough cerebral toxoplasmosis in patients with AIDS who are being treated with clarithromycin
146. The expanding spectrum of Bartonella infections. II: Cat-scratch disease
147. Clarithromycin in treatment of early Lyme disease: A pilot study
148. Single dose azithromycin compared to a four dose rifampin regimen for the eradication of meningococcal nasopharyngeal carriage
149. Activity of azithromycin as a blood schizonticide against rodent and human plasmodia in vivo
150. Activity of azithromycin (CP-62,993) and erythromycin against chloroquine-sensitive and chloroquine-resistant strains of Plasmodium falciparum in vitro
151. Prevention of bacterial endocarditis: Recommendations by the American Heart Association
152. Efficacy of azithromycin or clarithromycin for prophylaxis of viridans group streptococcus experimental endocarditis
153. Randomized, open-label trial of azithromycin plus ethambutol vs clarithromycin plus ethambutol as therapy for Mycobacterium avium complex bacteremia in patients with human immunodeficiency virus infection
154. Randomized secondary prevention trial of azithromycin in patients with coronary artery disease
155. Clinical and economic considerations in the treatment of acute exacerbations of chronic bronchitis
156. Effectiveness of azithromycin (AZ) in patients withcommunity-acquired pneumonia (CAP): An evidenced-based meta-analysis ofrandomized controlled trials
157. Macrolide resistance among Streptococcus pneumoniae and Streptococcus pyogenes isolates from outpatients in the USA
158. In vitro evaluation of activities of azithromycin, clarithromycin and sparfloxacin against Chlamydia trachomatis
159. Trovafloxacin, a new fluoroquinolone with potent activity against Streptococcus pneumoniae
160. In vitro activity of azithromycin against bacterial enteric pathogens
161. Erythromycin, clarithromycin and azithromycin: Use of frequency distribution curves, scattergrams, and regression analyses to compare in vitro activities and describe cross-resistance
162. A review of the comparative in vitro activities of 12 antimicrobial agents, with a focus on five new 'respiratory quinolones'
163. In vitro susceptibilities of 180 clinical isolates of Haemophilus influenzae to ampicillin, amoxycillin/clavulanate, cefaclor, cefuroxime, cefotaxime, clarithromycin and azithromycin
164. Comparative in vitro activity oe the new oral macrolide azithromycin
165. In vitro activities of azithromycin (CP 62,993), clarithromycin (A-56268; TE-031), erythromycin, roxithromycin and clindamycin
166. Comparative in vitro activity of azithromycin, clarithromycin, erythromycin and lomefloxacin against Mycoplasma pneumoniae, Mycoplasma hominis and Ureaplasma urealyticum
167. In vitro and in vivo activities of macrolides against Mycoplasma pneumoniae
168. Relative potencies of azithromycin, clarithromycin and five other orally administered antibiotics
169. Susceptibility of Streptococcus pyogenes to azithromycin, clarithromycin, erythromycin and roxithromycin in vitro
170. In vitro activities of azithromycin, clarithromycin, erythromycin and tetracycline against 13 strains of Chlamydia pneumoniae
171. Azithromycin versus cefaclor in the treatment of acute bacterial pneumonia
172. Comparison of three-day and five-day courses of azithromycin in the treatment of atypical pneumonia
173. Sparfloxacin versus clarithromycin in the treatment of community-acquired pneumonia
174. Comparison of grepafloxacin with clarithromycin in the treatment of community-acquired pneumonia
175. A double-blind, randomized, multicenter study in ambulatory community-acquired pneumonia comparing trovafloxacin with clarithromycin
176. Treatment of community-acquired pneumonia: A multicenter, double-blind randomized study comparing clarithromycin with erythromycin
177. Efficacy and safety of clarithromycin compared to cefixime as outpatient treatment of lower respiratory tract infections
178. Comparative study of azithromycin and amoxicillin/clavulanic acid in the treatment of lower respiratory tract infections
179. Comparison of azithromycin and erythromycin in the treatment of atypical pneumonia
180. Clarithromycin versus amoxicillin-clavulanic acid in the treatment of community-acquired pneumonia
181. Efficacy and safety of azithromycin versus benzylpenicillin or erythromycin in community-acquired pneumonia
182. Treatment of community-acquired pneumonia: A randomized comparison of sparfloxacin, amoxycillin-clavulanic acid and erythromycin
183. Comparison of grepafloxacin with clarithromycin in the treatment of community-acquired pneumonia (CAP) (abstract L-113)
184. Efficacy and safety of moxifloxacin vs clarithromycin for community-acquired pneumonia
185. Randomized, multicenter study of the efficacy and tolerance of azithromycin versus clarithromycin in the treatment of adults with mild to moderate community-acquired pneumonia - Azithromycin Study Group
186. Comparison of azithromycin versus clarithromycin in the treatment of patients with lower respiratory tract infections
187. A randomized comparative study on the safety and efficacy of clarithromycin and erythromycin in treating community-acquired pneumonia
188. Efficacy of a three day course of azithromycin in moderately severe community-acquired pneumonia
189. Azithromycin vs cefuroxime pllus erythromycin for empirical treatment of community-acquired pneumonia in hospitalized patients
190. Clinical efficacy of intravenous followed by oral azithromycin monotherapy in hospitalized patients with community-acquired pneumonia
191. Efficacy of a three-day course of azithromycin in the treatment of community-acquired pneumococcal pneumonia
192. Short course therapy with ceftibuten versus azithromycin in pediatric streptococcal pharyngitis
193. Comparison of clarithromycin and penicillin VK suspensions in the treatment of children with streptococcal pharyngitis and review of currently available alternative antibiotic therapies
194. Evaluation of the efficacy, safety and toleration of azithromycin vs penicillin V in the treatment of acute streptococcal pharyngitis in children: Results of a multicenter, open comparative study
195. Clarithromycin suspension vs penicillin V suspension in children with streptococcal pharyngitis
196. Comparative efficacy and safety of 3-day azithromycin and 10-day penicillin V treatment of group A beta-hemolytic streptococcal pharyngitis in children
197. Management of pediatric patients with group A beta-hemolytic Streptococcus pharyngitis: Treatment options
198. Azithromycin versus clarithromycin in the treatment of acute exacerbations of chronic bronchitis
199. Double-blind randomized study comparing the efficacies and safeties of a short (3-day) course of azithromycin and a 5-day course of amoxicillin in patients with acute exacerbations of chronic bronchitis
200. Efficacy of ciprofloxacin in acute bacterial exacerbations of complicated chronic bronchitis: Interim analysis
201. Clarithromycin versus cefaclor for the treatment of mild-to-moderate acute bacterial bronchitis
202. Comparative study of clarithromycin and ampicillin in the treatment of patients with acute exacerbations of chronic bronchitis
203. Clarithromycin 250 mg b.i.d. for 5 or 10 days in the treatment of adult patients with purulent bronchitis
204. Comparison of azithromycin and co-amoxiclav in the treatment of acute tracheobronchitis and acute infectious exacerbations of chronic bronchitis in adults
205. Multicenter comparison of clarithromycin and amoxicillin in the treatment of acute maxillary sinusitis
206. Efficacy of clarithromycin vs amoxicillin/clavulanate in the treatment of acute maxillary sinusitis
207. The comparative efficacy and safety of clarithromycin and amoxicillin in the treatment of outpatients with acute maxillary sinusitis
208. Azithromycin and amoxicillin in the treatment of acute maxillary sinusitis
209. A comparison of the efficacy, tolerability and safety of azithromycin and co-amoxclav in the treatment of sinusitis in adults
210. Comparison of azithromycin and co-amoxiclav in the treatment of otitis media in children
211. Clarithromycin and cefaclor suspensions in the treatment of acute otitis media in children
212. Comparative safety and efficacy of clarithromycin in the treatment of acute otitis media in children
213. A Comparative study of clarithromycin and amoxicillin suspensions in the treatment of pediatric patients with acute otitis media
214. Bacteriologic and clinical efficacy of amoxicillin/clavulanate vs azithromycin in acute otitis media
215. Clarithromycin vs amoxicillin suspensions in the treatment of pediatric patients with acute otitis media
216. Comparative study of the safety and efficacy of clarithromycin and amoxicillin-clavulanate in the treatment of acute otitis media in children
217. Multicenter comparative study of the efficacy and safety of azithromycin compared with amoxicillin/clavulanic acid in the treatment of paediatric patients with otitis media
218. Comparative studies of azithromycin in skin and soft tissue infections and sexually transmitted infections by Neisseria and Chlamydia species
219. Double-blind, double-dummy comparison of azithromycin and cephalexin in treatment of skin and skin structure infections
220. The role of azalide antibiotics in the treatment of Chlamydia
221. Azithromycin in the treatment of sexually transmitted disease